Background and Purpose—To report the result of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) 1 study, a phase 1 trial to evaluate the safety and efficacy of mechanical embolectomy in the cerebral vasculature.

Methods—MERCI 1 enrolled 30 patients in 7 US centers. Main inclusion criteria were: National Institutes of Health Stroke Scale score (NIHSS) ≥10; treatment performed within 8 hours from symptoms onset and contra-indication to intravenous thrombolysis; no large hypodensity on computed tomography; and occlusion of a major cerebral artery on the angiogram. Safety was defined by the absence of vascular injury or symptomatic intracranial hemorrhage. Efficacy was assessed by recanalization rate and clinical outcome at 1 month. Significant recovery was defined as 30-day modified Rankin of 0 to 2 in patients with baseline NIHSS 10 to 20 and 30-day modified Rankin of 0 to 3 in patients with baseline NIHSS >20. The procedures were performed with the Merci Retrieval System, a system specially designed for intracranial embolectomy.

Results—Twenty-eight patients were treated. Median NIHSS was 22. Median time from onset to completion of treatment was 6 hours and 15 minutes. Successful recanalization with mechanical embolectomy only was achieved in 12 (43%) patients, and with additional intra-arterial tissue plasminogen activator in 18 (64%) patients. There was one procedure related technical complication, with no clinical consequence. Twelve asymptomatic and no symptomatic intracranial hemorrhages occurred. At 1 month, 9 of 8 revascularized patients and 0 of 10 nonrevascularized patients had achieved significant recovery.

Conclusion—This phase 1 study shows that cerebral embolectomy with the Merci Retriever was safe and that successful recanalization could benefit a significant number of patients, even when performed in an extended 8-hour time window. (Stroke. 2004;35:2848-2854.)

Key Words: embolectomy ■ stroke, ischemic ■ thrombectomy ■ thrombolytic therapy

In 1995, the National Institute of Neurological Disorders and Stroke trials showed that intravenous tissue plasminogen activator (tPA) given within 3 hours from symptoms onset benefited stroke patients despite a 6.4% risk of symptomatic intracranial hemorrhage. However, although intravenous tPA was approved by the FDA in 1996 for treatment of stroke, only 2% to 3% of US stroke patients currently receive this treatment, mostly because of the limited therapeutic time window of 3 hours.

See Editorial Comment, page 2853

Extending this brief time window is critical for the majority of stroke patients to benefit from arterial recanalization. However, the risk-to-benefit ratio of intravenous tPA becomes rapidly unfavorable as time elapses, because less brain tissue can be saved while the risk of cerebral hemorrhage increases. Four clinical trials showed no benefit when intravenous tPA was given after 3 hours, and even in the NINDS trial most of the...
benefit of tPA over placebo was observed in the patients treated within 90 minutes from stroke onset.

Intra-arterial thrombolysis offered the hope of lengthening the time window for treatment. The PROACT II study of intra-arterial thrombolysis showed mild benefit when pro-urokinase was given within 6 hours of symptom onset despite a 10% rate of symptomatic intracranial hemorrhage. The FDA would not approve pro-urokinase unless a larger trial (PROACT 3) is performed, which is unlikely to occur.2

In an attempt to prolong the therapeutic time window and to treat patients with contra-indications to thrombolysis, we developed a mechanical system for endovascular embolectomy. Embolectomy should decrease the risk of hemorrhage because no (or minimal) thrombolitics are used, allowing the treatment of patients in a prolonged time window. Mechanical recanalization of the cerebral arteries presents unique challenges. Therefore, we designed the Merci Retrieval System specifically for percutaneous thromboembolectomy in brain vasculature. Here, we present the results of the phase I safety study in 30 patients.

Materials and Methods

Study Design

MERC I 1 was designed to evaluate the safety and technical efficacy of embolectomy in the cerebral arteries with the Merci Retriever in 30 consecutive patients. The study was performed in 7 US centers between May 16, 2001 and October 17, 2002, and the protocol was approved by the FDA under an international device exemption study, and by the institutional review boards at each center.

Patients were included for the trial if they: (1) had an acute ischemic stroke with NIHSS $\geq 10$; (2) presented after the 3-hour time window for intravenous thrombolysis and could be treated within 8 hours of symptom onset; (3) presented within 3 hours of symptom onset with a contraindication to intravenous thrombolysis; (4) were older than age 18; and (5) had a normal computed tomography (CT) scan or a CT scan showing a region of hypodensity less than one-third of the middle cerebral artery territory. Patients were excluded with: (1) glucose $<50$ mg/dL; (2) seizure at onset of stroke; (3) known prothrombin time $>15$ or hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulation therapy with international normalized ratio (INR) $>3.0$; (4) use of heparin within 48 hours with a partial thromboplastine time $>2$ times normal; (5) platelets $<50,000$; (6) severe hypertension defined as systolic blood pressure $>185$ or diastolic blood pressure $>110$; and (7) a CT scan revealing significant mass effect with midline shift.

Patients who met all clinical and CT scan criteria and for whom informed consent was obtained underwent cerebral angiography. Patients were then selected for embolectomy if the diagnostic angiogram showed an occlusion of the internal carotid artery, M1 segment of the middle cerebral artery, basilar artery, or vertebral artery. Patients were excluded if the angiogram showed a severe arterial stenosis proximal to the thrombus that, in the opinion of the investigator, would preclude thrombus removal.

Primary outcome was defined as arterial recanalization thrombolysis in myocardial infarction (TIMI; grade 2 or 3) without the occurrence of major complications defined as vessel perforation, arterial dissection, or embolization in a previously uninvolved territory. Secondary outcomes included the incidence of hemorrhage as determined by a head CT scan obtained at 24 hours, with a hemorrhage considered symptomatic if it was associated with a clinical deterioration of $>4$ points on the NIHSS, and NIHSS and modified Rankin score at 24 hours, 5 days, and 30 days after ictus. A significant recovery was defined as a 30-day modified Rankin score of 0 to 2 in patients with a baseline NIHSS of 10 to 20, and a 30-day modified Rankin score of 0 to 3 in patients with a baseline NIHSS $>20$.

The Merci Retrieval System

The Merci Retrieval System (Concentric Medical) consists of the Merci Retriever, the Merci Balloon Guide Catheter (BGC), and the Merci microcatheter. The BGC is a 9-French catheter with a large 2.1-mm lumen and a balloon located at its distal tip. The Merci Retriever uses superelastic technology, ie, the superelastic property of memory shaped nitinol (nickel titanium). The Merci Retriever is a tapered wire with 5 helical loops of decreasing diameter (from 2.8 mm to 1.1 mm) at its distal end. The Merci Retriever is advanced through the microcatheter in its straight configuration and resumes its pre-imposed helical shape once it is delivered into the occluded intracranial artery in order to ensnare the thrombus.

Procedure

Enrolled patients were given a bolus of 3000 U of heparin intravenously. The BGC was placed into the common or internal carotid artery for anterior circulation occlusion, or the subclavian artery for posterior circulation occlusion. Using standard cerebral catheterization techniques, the microcatheter was guided into the occluded vessel and passed beyond the thrombus. A selective angiogram was performed distal to the thrombus to evaluate the size and tortuosity of the distal arteries, where the Merci Retriever was to be deployed. The Merci Retriever was then advanced through the microcatheter and 2 to 3 helical loops were deployed beyond the thrombus (Figure 1). The Merci Retriever was then retracted at the contact of the thrombus, and the proximal loops were then deployed within the thrombus (Figure 2). The BGC balloon was inflated to control intracranial blood flow during removal of the thrombus and 5 clockwise rotations were applied to the Merci Retriever to further ensnare the thrombus (Figure 3). The Merci Retriever with the ensnared thrombus, and the microcatheter, were withdrawn together into the BGC lumen. Continuous aspiration was applied to the BGC to ensure complete evacuation of the thrombus. The balloon of the BGC was deflated to re-establish flow. On confirmation of complete evacuation of the thrombus (brisk reflux of blood), a repeat angiogram was performed. If the occlusion persists, then the procedure could be repeated up to 6 passes of the Merci Retriever. If it was unable to restore flow, then additional treatment was left at the discretion of the investigator.

Figure 1. After the microcatheter transverses the thrombus, the first loops of the Merci Retriever are delivered distal to the occlusion site.

Figure 2. The Merci Retriever is pulled back at the contact of the thrombus, additional loops are delivered within the thrombus, and the Merci Retriever is torqued to ensnare the thrombus.
discretion of the interventionalist. Figure 4 shows an example of thrombi removed from a carotid T occlusion (patient 9).

Results

Thirty patients were included in the study, and of these, 2 patients were enrolled but not treated. In one patient, visualization under fluoroscopy discovered that the thrombus extended into the M2 segment of the middle cerebral artery, and in the other patient the Merci Retriever was unable to get to the site of the thrombus because of tortuous anatomy.

Of the 28 patients treated, there were 14 males (50%) with a mean age of 68 (range, 28 to 93). Median baseline NIHSS was 22 (range, 12 to 39). Six patients presented within 3 hours of symptoms onset but had contraindication for intravenous tPA, and 21 patients presented between 3 and 8 hours after symptoms onset. One patient was treated outside the 8-hour time window (11 hours) because of a large diffusion/perfusion mismatch on MRI.

Occluded arteries included the intracranial internal carotid artery in 5 (18%), middle cerebral artery in 18 (64%), both internal carotid artery and middle cerebral artery in 3 (11%), and vertebro-basilar in 2 (7%) patients.

The median and mean time from baseline CT to groin puncture was 2 hours 23 minutes and 2 hours 29 minutes, respectively. The median and mean time from groin puncture to completion of treatment was 1 hour 14 minutes and 1 hour 27 minutes, respectively. The median and mean time of stroke symptom onset to completion of treatment were 6 hours 15 minutes and 6 hours 1 minute, respectively.

Two patients (7%) received only magnetic resonance imaging and no CT scan before to enrollment. There were 3 (11%) protocol deviations with regard to prothrombin time. These 3 patients had a prothrombin time >15 seconds; however, their INR was <3, as required by protocol.

Successful recanalization (TIMI 2 to 3) was achieved in 12 (43%) patients with the Merci Retriever only. Eight patients (29%) received intra-arterial tPA after unsuccessful recanalization. Six had successful recanalization (TIMI 2 or 3) after administration of the drug.

With additional intra-arterial tPA, successful recanalization was obtained in 18 (64%) patients.

Table 1 gives, for each patient, the NIHSS score, recanalization, possible treatment with thrombolysis, NIHSS, and modified Rankin score at 24 hours, 5 days, and 30 days.

Table 2 presents patient outcome dichotomized according to baseline NIHSS (10 to 20 or >20) and recanalization. In the 13 patients who presented with moderate to severe stroke (NIHSS 10 to 20), 6 out of 10 revascularized patients achieved significant recovery (modified Rankin score 0 to 2), whereas none of the 3 patients who were not revascularized achieved significant recovery. In the 15 patients who presented with very severe stroke (NIHSS >20), 3 out of 8 revascularized patients achieved significant recovery (modified Rankin score 0 to 3), whereas none of the 7 patients who were not revascularized achieved significant recovery. Overall, 9 of 18 (50%) revascularized patients and 0 of 10 nonrevascularized patients achieved significant recovery.

There was one technical complication when the tip of the Merci Retriever detached from the device. Another Merci Retriever was used to ensnare the detached tip and successfully remove it from the vasculature. This had no clinical consequence.

There were 10 deaths (36%) during the 30-day follow-up period. These patients died from 1 to 28 days after the procedure (mean, 6 days). All deaths were determined to be related to the disease state of the patient and not to the study device.

Twelve patients (43%) had asymptomatic intracranial hemorrhages discovered on the 24-hour CT scan required per protocol. There were no symptomatic hemorrhages.
This study shows that embolectomy with the Merci Retriever was safe. There was no angiographic or clinical evidence of vascular injury or emboli into previously uninvolved arteries. Successful recanalization with thrombectomy alone was obtained in 43%. The total recanalization rate, including those patients successfully revascularized with intra-arterial thrombolytics, was 64%. Among the 18 patients who were revascularized, 50% (9/18) made a significant recovery (defined as 30-day modified Rankin score 0 to 2 when baseline NIHSS 10 to 20 and modified Rankin score 0 to 3 when baseline NIHSS $\geq$20). Significant recovery was observed in 9 of 18 recanalized patients and 0 of 10 nonrecanalized patients.

### Discussion

This study shows that embolectomy with the Merci Retriever was safe. There was no angiographic or clinical evidence of vascular injury or emboli into previously uninvolved arteries. Successful recanalization with thrombectomy alone was obtained in 43%. The total recanalization rate, including those patients successfully revascularized with intra-arterial thrombolytics, was 64%. Among the 18 patients who were revascularized, 50% (9/18) made a significant recovery (defined as 30-day modified Rankin score 0 to 2 when baseline NIHSS 10 to 20 and modified Rankin score 0 to 3 when baseline NIHSS $\geq$20). Significant recovery was observed in 9 of 18 recanalized patients and 0 of 10 nonrecanalized patients.

### Table 1. Patient Outcomes

<table>
<thead>
<tr>
<th>Patient</th>
<th>NIHSS Pretreatment</th>
<th>Artery Occluded</th>
<th>TIMI After Embolectomy</th>
<th>IA t-PA (dose)</th>
<th>TIMI After Embolectomy and Thrombolysis</th>
<th>NIHSS 5 Days</th>
<th>NIHSS 30 Days</th>
<th>Rankin 30 Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>19</td>
<td>ICA III</td>
<td>n/a</td>
<td>n/a</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>26</td>
<td>ICA I</td>
<td>n/a</td>
<td>n/a</td>
<td>30</td>
<td>Death 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>25</td>
<td>MCA 0</td>
<td>n/a</td>
<td>n/a</td>
<td>21</td>
<td>16</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>14</td>
<td>MCA 0</td>
<td>15 mg</td>
<td>III</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>24</td>
<td>MCA I</td>
<td>n/a</td>
<td>n/a</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>13</td>
<td>MCA 0</td>
<td>7 mg</td>
<td>III</td>
<td>2</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>18</td>
<td>ICA + MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>20</td>
<td>37</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>19</td>
<td>MCA 0</td>
<td>n/a</td>
<td>n/a</td>
<td>15</td>
<td>16</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>26</td>
<td>ICA + MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>12</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Not Treated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>16</td>
<td>MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>4</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>39</td>
<td>Vertebral I</td>
<td>n/a</td>
<td>n/a</td>
<td>19</td>
<td>7</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>19</td>
<td>MCA I</td>
<td>n/a</td>
<td>n/a</td>
<td>18</td>
<td>8</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>17</td>
<td>ICA + MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>22</td>
<td>Death 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>38*</td>
<td>MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>16</td>
<td>11</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>23</td>
<td>MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>23</td>
<td>20</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Not Treated</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>22</td>
<td>MCA 0</td>
<td>n/a</td>
<td>n/a</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>29</td>
<td>MCA III</td>
<td>n/a</td>
<td>n/a</td>
<td>15</td>
<td>15</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>18</td>
<td>MCA 0</td>
<td>6 mg</td>
<td>II</td>
<td>12</td>
<td>9</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>24</td>
<td>MCA II</td>
<td>n/a</td>
<td>n/a</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>36</td>
<td>Basilar I</td>
<td>n/a</td>
<td>n/a</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>16</td>
<td>MCA 0</td>
<td>20 mg</td>
<td>I</td>
<td>25</td>
<td>13</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>12</td>
<td>ICA III</td>
<td>n/a</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>17</td>
<td>ICA III</td>
<td>n/a</td>
<td>n/a</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td>28</td>
<td>MCA I</td>
<td>20 mg</td>
<td>II</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td>21</td>
<td>ICA 0</td>
<td>15 mg</td>
<td>0</td>
<td>Death 6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td>26</td>
<td>ICA 0</td>
<td>10 mg</td>
<td>II</td>
<td>37</td>
<td>Death 6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td>23</td>
<td>MCA I</td>
<td>20 mg</td>
<td>III</td>
<td>13</td>
<td>6</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td>15</td>
<td>MCA III</td>
<td>n/a</td>
<td>n/a</td>
<td>0</td>
<td>0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*NIHSS performed on sedated patient.
N/a indicates not available; MCA, middle cerebral artery; ICA, internal cerebral artery.

### Table 2. NIHSS and Recanalization vs Outcome

<table>
<thead>
<tr>
<th>Baseline NIHSS</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIHSS 10–20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>5</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>NIHSS $\geq$20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>No</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td>0</td>
<td>5</td>
</tr>
</tbody>
</table>

*Recanalization: revascularization (TIMI II–III) obtained after embolectomy and intra-arterial t-PA. Bold numbers indicate significant recovery (modified Rankin score 0 to 2 when baseline NIHSS 10 to 20 and modified Rankin score 0 to 3 when baseline NIHSS $\geq$20). Significant recovery was observed in 9 of 18 recanalized patients and 0 of 10 nonrecanalized patients.
hours, making the maximal time from symptom onset to recanalization 8 hours. As PROACT II demonstrated benefit from intra-arterial thrombolysis despite a 10% symptomatic hemorrhage rate, we postulated that embolectomy could be beneficial even in an extended time window of 8 hours. The second population of MERCI 1 was patients who presented within 3 hours of stroke onset but in whom intravenous thrombolysis was contraindicated. We postulated that embolectomy would be beneficial in these patients because it would not increase the risk of hemorrhage.

Only patients with moderate to severe stroke were enrolled in the MERCI 1 study. An NIHSS ≥10 was chosen because these patients generally have a poor outcome and small chance of spontaneous good recovery. An NIHSS ≥10 is also selective for patients with large vessel occlusion at angiography. In the Emergency Management of Stroke study, 78% of patients with an NIHSS ≥10 and only 33% of patients with an NIHSS <10 had an arterial occlusion at angiography. The phase 2 MERCI study, a prospective study of efficacy of embolectomy in 150 patients with moderate and severe stroke, is currently underway in 25 US centers. If it confirms the results of MERCI 1, then mechanical embolectomy with the Merci Retriever could address the major drawback of intravenous or intra-arterial thrombolysis, namely that the risk of hemorrhage compared with the potential benefit of revascularization becomes rapidly unacceptable when the time window is extended beyond 3 hours. Although the number of patients in this phase 1 study is small, these results suggest that mechanical embolectomy performed within 8 hours from symptom onset in moderate and severe stroke may benefit half the cohort of successfully recanalized patients with minimal risk of symptomatic hemorrhage or device-related complications.

Acknowledgments


Emory University (0): F. Tong, J. Dion, M. Frankel.


Stanford University (0): M. Marks, G. Albers, H. Do, A. Hsia, D. Tong, C. Wijman.

Emory University (0): F. Tong, J. Dion, M. Frankel.

References


3. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, Von Kummer R. For the ECASS study group. Intravenous thrombolysis with recombinant
thrombolysis procedures, with the data granted by PRO-AC T II, might help to back up the clots removing, left at ischemic stroke: Emergency Management of Stroke (EMS) bridging trial. Stroke. 1999;30:2598–2605.

Gobin et al  The MERCI I Study 2853

A Mercy to Victims of Cerebrovascular Diseases

The year 2004 has been a year of reinforcing the idea of treating ischemic stroke. Measures for recanalization per endovascular approach are again proved to be feasible in the brain vessels. In this issue of Stroke, Gobin et al report an unprecedented, promising phase I feasibility study of removing clots from occluded vessels by corkscrew Mechanical Embolus Removal in Cerebral Ischemia (Merci) Retrieval System.1 Treating ischemic stroke by embolectomy is not a new concept; however, until this year, the efficacy of the treatment is emerging and not too invasive.

Recently, the US Food and Drug Administration cleared the device for clot removing. Clot removing might be a reasonable way to treat the occluded brain vessels in practice, but the efficacy of treating acute ischemic stroke by this device is not yet unyielding; thus, the indication should be taken as pending approval. The requirements for approval of the efficacy might be as comparable to those applied to prourokinase from the Prolyse in Acute Cerebral Thromboembolism Trial (PROACT) II.2


Editorial Comment

The year 2004 has been a year of reinforcing the idea of treating ischemic stroke. Measures for recanalization per endovascular approach are again proved to be feasible in the brain vessels. In this issue of Stroke, Gobin et al report an unprecedented, promising phase I feasibility study of removing clots from occluded vessels by corkscrew Mechanical Embolus Removal in Cerebral Ischemia (Merci) Retrieval System.1 Treating ischemic stroke by embolectomy is not a new concept; however, until this year, the efficacy of the treatment is emerging and not too invasive.

Recently, the US Food and Drug Administration cleared the device for clot removing. Clot removing might be a reasonable way to treat the occluded brain vessels in practice, but the efficacy of treating acute ischemic stroke by this device is not yet unyielding; thus, the indication should be taken as pending approval. The requirements for approval of the efficacy might be as comparable to those applied to prourokinase from the Prolyse in Acute Cerebral Thromboembolism Trial (PROACT) II.2

Although IV recombinant tissue plasminogen activator has been available in many European and Asian countries since 2002, the short time window ruthlessly limited the treatment incidence. Prehospital delay has been more than enough.3 As shown in this study, limited to no patients had been treated in participating centers. Patients were additionally excluded if the arterial stenosis was proximal to the thrombus, in the opinion of the investigator. Either the number of patients screened or the number of the angiograms done before the 30 eligible patients had been enrolled were not studied. These statistics will help to support the generalization and the feasibility of this technique. Until those figures are obtainable, this device might have the prospect to show efficacy in the real world outside the IV thrombolysis.

The clot removing might not be too invasive. The balloon inflation for the control of antegrade blood flow might reduce the flow-induced shear stress and potential fragmentation of the thrombus, but the duration and the vessels injury should be cautiously adjusted.

There were 6 successful recanalized intra-arterial procedures out of 8 patients among 14 patients with unsuccessful clot retrieval. This indicates that intra-arterial thrombolysis procedures, with the data granted by PROACT II, might help to back up the clots removing, left at the discretion of the interventionalist.

As in 2000, emergency cerebral angiography is out of the question in most hospitals. Thrombolysis In Myocardial Infarction (TIMI) grading is not a common language among stroke experts. There is a need for uniform definitions of collateral flow, degree of recanalization, assessment of perfusion, and infarct size to be applied in trials (such as phase 1 MERCI) to avoid confusing vascular analysis from the local principle investigators. Again, this is the time to take the great “technological leap” and
incorporate vascular testing into the routine assessment of acute ischemic stroke.4

Though not perfect, the noninvasive evaluation of patients with suspected intracranial artery stenosis or occlusion might be available soon.5 But the attempts of adapting these measures in acute stroke treatment have rarely been met. Future studies concerning avoidance of the negative cerebral angiograms are warranted, such as using MRI, computed tomographic angiograms, or transcranial Doppler in the screening phase. Although the National Institutes of Health Stroke Scale could serve as a useful tool, the evidence to prove the occlusion in order to initiate the invasive treatment is crucial.

Although the desmoteplase thrombolysis selected by MRI perfusion/diffusion mismatch and intracranial stenting6 showed potential in 2004, the expenditure of these great technological leaps is sobering. The cost of the treatment in the few hours after stroke might be more than the amount for whole short-term hospitalization in certain welfare areas.7 Although with the benefits, the phase 2 MERCI study with 141 patients will struggle to support the use of this device outside the current participating centers. The estimates of effectiveness and cost-effectiveness of the device would be difficult or imprecise but desirable. With the estimates at hand and affirmative, the device would be really a mercy to victims of cerebrovascular diseases.

Ku-Chou Chang, MD, Guest Editor
Assistant Professor of Neurology
First Department of Neurology
Chang Gung Memorial Hospital
Kaohsiung, Taiwan

References
MERCI 1: A Phase 1 Study of Mechanical Embolus Removal in Cerebral Ischemia

Stroke. 2004;35:2848-2854; originally published online October 28, 2004;
doi: 10.1161/01.STR.0000147718.12954.60
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://stroke.ahajournals.org/content/35/12/2848

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org/subscriptions/